Clinical Trials Logo

Select Advanced Solid Tumors clinical trials

View clinical trials related to Select Advanced Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT06402201 Recruiting - Clinical trials for Select Advanced Solid Tumors

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.

NCT ID: NCT04262466 Recruiting - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Start date: February 25, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

NCT ID: NCT03973333 Terminated - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Start date: May 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

NCT ID: NCT03515551 Terminated - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Start date: June 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

IMCnyeso is a bispecific fusion protein designed for the treatment of cancers that express NY-ESO-1 and/or LAGE-1A. This was a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in HLA-A*02:01-positive adult participants whose cancer is positive for NY-ESO-1 and/or LAGE-A1.

NCT ID: NCT02705482 Completed - Clinical trials for Select Advanced Solid Tumors

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Start date: March 30, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.